Similar articles

• Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.

  Smith PF, Booker BM, Ogundele AB, Kelchin P. Smith PF, et al. Diagn Microbiol Infect Dis. 2005 Jul;52(3):255-9. doi: 10.1016/j.diagmicrobio.2005.02.015. Diagn Microbiol Infect Dis. 2005. PMID: 15935606
• Quinupristin/dalfopristin and linezolid: spectrum of activity and potential roles in therapy--a status report.

  Batts DH, Lavin BS, Eliopoulos GM. Batts DH, et al. Curr Clin Top Infect Dis. 2001;21:227-51. Curr Clin Top Infect Dis. 2001. PMID: 11572153 Review. No abstract available.
• Antibiotics for gram-positive bacterial infections. Vancomycin, teicoplanin, quinupristin/dalfopristin, and linezolid.

  Lundstrom TS, Sobel JD. Lundstrom TS, et al. Infect Dis Clin North Am. 2000 Jun;14(2):463-74. doi: 10.1016/s0891-5520(05)70258-0. Infect Dis Clin North Am. 2000. PMID: 10829266 Review.
• In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin.

  Anastasiou DM, Thorne GM, Luperchio SA, Alder JD. Anastasiou DM, et al. Int J Antimicrob Agents. 2006 Nov;28(5):385-8. doi: 10.1016/j.ijantimicag.2006.07.017. Int J Antimicrob Agents. 2006. PMID: 17046205 Review.
• Linezolid pharmacokinetics and pharmacodynamics in clinical treatment.

  Dryden MS. Dryden MS. J Antimicrob Chemother. 2011 May;66 Suppl 4:iv7-iv15. doi: 10.1093/jac/dkr072. J Antimicrob Chemother. 2011. PMID: 21521707 Review.